The CHARM program consisted of 3 component trials, each comparing candesartan with placebo in a distinct population of patients with symptomatic heart failure [9]: CHARM-Alternative: patients with ...

Heart failure presents a growing public health problem both in Estonia and across Europe. At the same time, its timely ...

A new Scientific Statement from the Heart Failure Society of America (HFSA) challenges longstanding ambiguity in the classification and treatment of heart failure with mildly reduced ejection fraction ...

A substudy of the CHARM trial (see Trial Glossary below for expansion of all trial names mentioned in this article) has shown that the angiotensin receptor blocker (ARB) candesartan reduces the risk ...

Please provide your email address to receive an email when new articles are posted on . CAD was significantly prognostic of all-cause mortality in patients with heart failure. Mortality risk was ...

The study shows that disease severity and poor prognosis in ATTR-CM are associated with elevated levels of mid-regional ...

Heart failure presents a growing public health problem both in Estonia and across Europe. At the same time, ...

Heart failure risk prediction improves when gut-derived biomarkers are added to traditional models, revealing residual risk ...

UVA Health researchers have developed a powerful new risk assessment tool for predicting outcomes in heart failure patients. The researchers have made the tool publicly available for free to ...

Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing significant correlations. Higher scores correlate with increased heart failure ...

Electrocardiograms (EKGs) can help diagnose heart failure by measuring the electrical activity of the heartbeat. Doctors use EKGs alongside other tests to help assess heart failure. Heart failure ...

Background Cancer survivors often face the risk of developing heart failure (HF) as a result of their previous cancer therapy ...